The registration and commercialization for new medication is a highly demanding and technical challenge, considering the development of a reliable and sustainable manufacturing process for production of safe and effective products in compliance with global regulatory requirements.
Our manufacturing is according to GMP (Good Manufacturing Practice regulations). A new facility of premium biotechnological manufacturing with increased capacity, diversified R&D capabilities and exceptional know-how to produce the high-quality oncolytic ECHO-7 virus will be opened in 2018.
Reliable production of consistent oncotropic, non-pathogenic virus.
Disease – specific oncolytic virotherapy development.